Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury ; volume:17 ; number:1 ; day:30 ; month:7 ; year:2018 ; pages:1-14 ; date:12.2018
Cardiovascular diabetology ; 17, Heft 1 (30.7.2018), 1-14, 12.2018
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Aroor, Annayya R.
- Beteiligte Personen und Organisationen
-
Das, Nitin A.
Carpenter, Andrea J.
Habibi, Javad
Jia, Guanghong
Ramirez-Perez, Francisco I.
Martinez-Lemus, Luis
Manrique-Acevedo, Camila M.
Hayden, Melvin R.
Duta, Cornel
Nistala, Ravi
Mayoux, Eric
Padilla, Jaume
Chandrasekar, Bysani
DeMarco, Vincent G.
SpringerLink (Online service)
- DOI
-
10.1186/s12933-018-0750-8
- URN
-
urn:nbn:de:101:1-2018100121373564301197
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aroor, Annayya R.
- Das, Nitin A.
- Carpenter, Andrea J.
- Habibi, Javad
- Jia, Guanghong
- Ramirez-Perez, Francisco I.
- Martinez-Lemus, Luis
- Manrique-Acevedo, Camila M.
- Hayden, Melvin R.
- Duta, Cornel
- Nistala, Ravi
- Mayoux, Eric
- Padilla, Jaume
- Chandrasekar, Bysani
- DeMarco, Vincent G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Die Glukosesenkung mit dem SGLT2-Hemmer Empagliflozin verbessert die Atheroskleroseregression in der hyperglykämischen STZ-diabetischen Maus
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Die Glukosesenkung mit dem SGLT2-Hemmer Empagliflozin verbessert die Atheroskleroseregression in der hyperglykämischen STZ-diabetischen Maus
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Der Einfluss des SGLT2-Inhibitors Empagliflozin auf den Ionenhaushalt im murinen und humanen Kardiomyozyten
Repurposing SGLT2 inhibitors: treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
Mechanism of action of the SGLT2 inhibitor empagliflozin on endothelial dysfunction : An in vitro study
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice